MonoSol faces patent claim setback; Leonardo and NanoMedical seal drug delivery system development deal;

> Heparinex has nailed down new funding to fuel development of its drug delivery system, which connects the heparosan sugar molecule to a drug so it stays in the body longer and is more active. Story

> The U.S. Patent Office denied all 191 claims MonoSol filed against BioDelivery Sciences International regarding its thin film manufacturing process, BioDelivery announced. Release

> Leonardo Biosystems and NanoMedical Systems inked a deal to develop and enact a commercial process to make nanoporous silicon particles for Leonardo's multi-stage drug delivery system. Release

> Selecta Biosciences launched a Phase I clinical trial for a new smoking vaccine, which uses synthetic nanoparticles to deliver the treatment. Story

> Drug companies are increasingly looking at new forms of innovative delivery technology to sustain growth as more of their big patents expire, according to Lux Research. Release

> Quest PharmaTech ($QPT) will be publishing early-stage research results on the use of nanotechnology-based photodynamic therapy products to treat cancer. Release

Suggested Articles

Xeris scored an FDA fast track designation for its diazepam formulation, delivered via autoinjector, to treat acute repetitive seizures.

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.